Šw‰ï”­•\2024 

�y�‘�ÛŠw‰ï�@ˆê”ʉ‰‘è�@Œû“ª”­•\�z


Inatani M, Kohama I, Chu A
Two-year post-market surveillance of safety and clinical outcomes of iStent inject® W combined with phacoemulsification in Japanese eyes with open-angle glaucoma
7th Asia-Pacific Glaucoma Congress, Manila, Philippines SMX Convention Center, May 24-26


Shogo Arimura
A deep learning model can detect the eyes receiving glaucoma medications based on anterior segment images
The 17th Joint Meeting of Japan-Korea-China Ophthalmologists, Congress Haneda Square, Nov 9


Iwasaki K.
Surgical outcomes of Baerveldt glaucoma implant versus Ahmed glaucoma valve in neovascular glaucoma: A multicenter study
The 17th Joint Meeting of Japan-Korea-China Ophthalmologists, Congress Haneda Square, Nov 9


�y�‘�ÛŠw‰ï�@ˆê”ʉ‰‘è�@ƒ|ƒXƒ^�[”­•\�z


Takamura Y, Sugihara Y, Yamada Y, Morioka M, Gozawa M, Inatani M, J-CREST (Japan Clinical Retina Study Group)
Characterization of visually impaired pacients with diabetes mellitus in Japan
ARVO 2024 The Seattle Convention Center, Seattle, USA May 4-9


Yamada Y, Ichihashi Y, Takamura Y, Hirano T, Shimura M, Yoneda K, Konno K, Inatani M
Flare levels after intravitreal injection of brolucizumab for diabetic macular edema
ARVO 2024 The Seattle Convention Center, Seattle, USA May 4-9



�y�‘“àŠw‰ï�i‘S�‘�j ƒVƒ“ƒ|ƒWƒEƒ€�z


îà‘º�@‰À�O
“œ”A•a–Ô–Œ�Ç�fŽ@ƒKƒCƒhƒ‰ƒCƒ“‚̉ü’ù‚ÉŒü‚¯‚Ä
‘æ128‰ñ“ú–{Šá‰ÈŠw‰ï‘�‰ï�@‹³ˆçƒZƒ~ƒi�[
—ߘa6”N4ŒŽ18-21“ú�@�@“Œ‹ž�‘�ÛƒtƒH�[ƒ‰ƒ€


îà‘º�@‰À�O
�RVEGFŽ¡—ÃŽž‘ã‚̃Œ�[ƒU�[Œõ‹ÃŒÅ‚ƃXƒeƒ�ƒCƒh‚ÌŠˆ—p–@
‘æ128‰ñ“ú–{Šá‰ÈŠw‰ï‘�‰ï�@
—ߘa6”N4ŒŽ18-21“ú�@�@“Œ‹ž�‘�ÛƒtƒH�[ƒ‰ƒ€


îà‘º�@‰À�O
“œ”A•a‰©”Á•‚Žî‚É‚¨‚¯‚é�R VEGF Ž¡—ÂÌ�Å“K‰»
‘æ40‰ñ“ú–{Šá�zŠÂŠw‰ï
—ߘa6”N7ŒŽ19-20“ú�@•Ÿ“‡Œ§ŒSŽRŽs


ˆî’J�@‘å
Stent infinite and iDose
New glaucoma surgery trend from overseas
‘æ35‰ñ“ú–{—Γà�áŠw‰ï�@
—ߘa6”N9ŒŽ19-22“ú�@�@ƒAƒNƒŠƒG‚Ђ߂¶


’Ò�@—²�G
—Γà�á�«Ž‹�_Œo�ǃ‚ƒfƒ‹ƒ}ƒEƒX‚É‚¨‚¯‚é–Ô–Œ�_Œo�ß�×–E޲�õ‚̃~ƒgƒRƒ“ƒhƒŠƒA—±Žq‰ð�Í
‘æ35‰ñ“ú–{—Γà�áŠw‰ï�@
—ߘa6”N9ŒŽ19-22“ú�@�@ƒAƒNƒŠƒG‚Ђ߂¶


Šâí•�@Œ’‘¾˜Y
‘OŠá•”ŒŸ�¸‚̃Aƒbƒvƒf�[ƒg
‘æ35‰ñ“ú–{—Γà�áŠw‰ï�@‹³ˆçƒZƒ~ƒi�[
—ߘa6”N9ŒŽ19-22“ú�@�@ƒAƒNƒŠƒG‚Ђ߂¶


îà‘º�@‰À�O
“O’ê“¢˜_! “œ”A•a–Ô–Œ�Ç�E‰©”Á•‚Žî�f—ẪNƒŠƒjƒJƒ‹ƒNƒGƒXƒ`ƒ‡ƒ“(CQ)
‘æ78‰ñ“ú–{—Õ�°Šá‰ÈŠw‰ï�@ƒCƒ“ƒXƒgƒ‰ƒNƒVƒ‡ƒ“ƒR�[ƒX
—ߘa6”N11ŒŽ14-17“ú�@�@�‘—§‹ž“s�‘�Û‰ïŠÙ


îà‘º�@‰À�O
‚±‚ñ‚ÈŽž�A‚Ç‚¤‘Å‚Â�H�[–Ô–ŒƒŒ�[ƒU�[‚ð�Ä�l‚µ‚悤�[
‘æ78‰ñ“ú–{—Õ�°Šá‰ÈŠw‰ï�@ƒCƒ“ƒXƒgƒ‰ƒNƒVƒ‡ƒ“ƒR�[ƒX
—ߘa6”N11ŒŽ14-17“ú�@�@�‘—§‹ž“s�‘�Û‰ïŠÙ


Šâí•�@Œ’‘¾˜Y
—¬�o˜H�ÄŒš�p‚Ì“K‰ž
‘æ78‰ñ“ú–{—Õ�°Šá‰ÈŠw‰ï
—ߘa6”N11ŒŽ14-17“ú�@�@�‘—§‹ž“s�‘�Û‰ïŠÙ


‘哈�G�K�A�‚‘º‰À�O
“œ”A•a‰©”Á•‚Žî‚ɑ΂·‚éSGLT2‘jŠQ–ò‚̉e‹¿
‘æ31‰ñ“ú–{“œ”A•aŠáŠw‰ï‘�‰ï
—ߘa7”N1ŒŽ25-26“ú�@�@‰«“êŽs


�‚‘º�@‰À�O
–Ñ�׌ŒŠÇᎂ©‚猩‚铜”A•a‰©”Á•‚Žî�f—Ã
‘æ31‰ñ“ú–{“œ”A•aŠáŠw‰ï‘�‰ï
—ߘa7”N1ŒŽ25-26“ú�@�@‰«“êŽs


�y�‘“àŠw‰ï�i‘S�‘�j“Á•Ê�u‰‰�z


�‚‘º�@‰À�O
‘f–p‚È‹^–â‚ÉŒü‚«�‡‚Á‚Ä•à‚ñ‚¾“œ”A•aŠá�‡•¹�ǂ̌¤‹†
‘æ31‰ñ“ú–{“œ”A•aŠáŠw‰ï‘�‰ï
—ߘa7”N1ŒŽ25-26“ú�@�@‰«“êŽs


�y�‘“àŠw‰ï�i‘S�‘�jƒ��[ƒJ�[‹¤�ÃZƒ~ƒi�[�z


ˆî’J�@‘å
Žs”̌㒲�¸2”N�¬�тƒ·ŠúˆÀ‘S�«‚𑬕ñ‚µ‚Ü‚·�I
‘æ128‰ñ“ú–{Šá‰ÈŠw‰ï‘�‰ï�@ƒOƒ‰ƒEƒRƒXƒWƒƒƒpƒ“�@ƒ‚�[ƒjƒ“ƒOƒZƒ~ƒi�[
—ߘa6”N4ŒŽ18-21“ú�@�@“Œ‹ž�‘�ÛƒtƒH�[ƒ‰ƒ€


ˆî’J�@‘å
–ò•¨“®‘Ԃ𓥂܂¦‚½Ž¡—ÃAƒvƒ��[ƒ`
—Γà�Ꭱ—ÂÌ�hWhat�fs more�h
‘æ128‰ñ“ú–{Šá‰ÈŠw‰ï‘�‰ï�@�çŽõ�»–ò�@ƒ‰ƒ“ƒ`ƒ‡ƒ“ƒZƒ~ƒi�[
—ߘa6”N4ŒŽ18-21“ú�@�@“Œ‹ž�‘�ÛƒtƒH�[ƒ‰ƒ€


ˆî’J�@‘å
ƒGƒrƒfƒ“ƒX‚©‚ç•R‰ð‚­—Γà�Ꭱ—Ã�`—Γà�á“_Šá–òŠá“àˆÚ�s•Ò�`
ƒGƒrƒfƒ“ƒX‚©‚ç•R‰ð‚­—Γà�Ꭱ—Ã�`‰ß‹Ž�EŒ»�Ý�E–¢—ˆ�`
‘æ128‰ñ“ú–{Šá‰ÈŠw‰ï‘�‰ï�@ƒ”ƒBƒAƒgƒŠƒX�»–ò�@ƒCƒuƒjƒ“ƒOƒZƒ~ƒi�[
—ߘa6”N4ŒŽ18-21“ú�@�@“Œ‹ž�‘�ÛƒtƒH�[ƒ‰


ˆî’J�@‘å
‘±”­—Γà�á‚ÌŽè�p‚Í‚±‚¤‚·‚é‚ñ‚¾�I
‘æ128‰ñ“ú–{Šá‰ÈŠw‰ï‘�‰ï�@ƒAƒ‹ƒRƒ“�@ƒ‰ƒ“ƒ`ƒ‡ƒ“ƒZƒ~ƒi�[
—ߘa6”N4ŒŽ18-21“ú�@�@“Œ‹ž�‘�ÛƒtƒH�[ƒ‰ƒ€


îà‘º�@‰À�O
“�«DME‚ɑ΂·‚é–Ñ�׌ŒŠÇᎂðˆÓޝ‚µ‚½ƒoƒr�[ƒXƒ‚‚É‚æ‚鎡—Ã�í—ª
‘æ128‰ñ“ú–{Šá‰ÈŠw‰ï‘�‰ï�@’†ŠO�»–ò�@ƒ‰ƒ“ƒ`ƒ‡ƒ“ƒZƒ~ƒi�[
—ߘa6”N4ŒŽ18-21“ú�@�@“Œ‹ž�‘�ÛƒtƒH�[ƒ‰ƒ€


îà‘º�@‰À�O
“œ”A•a‚ł̎¸–¾ƒ[ƒ�‚ð–ÚŽw‚µ‚Ä
‘æ128‰ñ“ú–{Šá‰ÈŠw‰ï‘�‰ï�@‚í‚©‚à‚Æ�»–ò�@ƒ‚�[ƒjƒ“ƒOƒZƒ~ƒi�[
—ߘa6”N4ŒŽ18-21“ú�@�@“Œ‹ž�‘�ÛƒtƒH�[ƒ‰ƒ€


îà‘º�@‰À�O
ƒxƒIƒrƒ…‚ª’˜Œø‚·‚éDME�Ç—á‚É“Á’¥‚Í‚ ‚é‚©�H
‘æ30‰ñ“ú–{“œ”A•aŠáŠw‰ï‘�‰ï�@ƒmƒoƒ‹ƒeƒBƒXƒtƒ@�[ƒ}�@ƒAƒtƒ^ƒk�[ƒ“ƒZƒ~ƒi�[
—ߘa6”N6ŒŽ14-15“ú�@�@�Ô�âƒCƒ“ƒ^�[ƒVƒeƒBƒRƒ“ƒtƒ@ƒŒƒ“ƒX


Œã‘ò�@�½
PDRŽè�p�A‚¨–ð‚¾‚¿ƒc�[ƒ‹
‘æ30‰ñ“ú–{“œ”A•aŠáŠw‰ï‘�‰ï�@“ú–{ƒAƒ‹ƒRƒ“�@ƒ‰ƒ“ƒ`ƒ‡ƒ“ƒZƒ~ƒi�[
—ߘa6”N6ŒŽ14-15“ú�@�@�Ô�âƒCƒ“ƒ^�[ƒVƒeƒBƒRƒ“ƒtƒ@ƒŒƒ“ƒX


ˆî’J�@‘å
—Γà�ኳŽÒ‚Ì”’“à�áŽè�p
ƒNƒ�ƒXƒI�[ƒo�[—Γà�ኳŽÒ‚Ì”’“à�áŽè�p
‘æ63‰ñ“ú–{”’“à�áŠw‰ï‘�‰ï�@�çŽõ�»–ò�@ƒXƒC�[ƒcƒZƒ~ƒi�[
—ߘa6”N8ŒŽ23-24“ú�@�@“ú–{ˆã‰È‘åŠw•�‘ �¬�™•a‰@


ˆî’J�@‘å
‚±‚±‚܂Ŗ£‚¹‚Ü‚·�IHydrus®—Γà�áƒ}ƒCƒNƒ�ƒXƒeƒ“ƒg‚Ì“Á’¥‚ƃKƒCƒhƒ‰ƒCƒ“
�V‚½‚ÈMIGSŽž‘ã‚Ì–‹ŠJ‚¯�`‚±‚±‚܂Ŗ£‚¹‚Ü‚·�IHydrus—Γà�áƒ}ƒCƒNƒ�ƒXƒeƒ“ƒg�`
‘æ35‰ñ“ú–{—Γà�áŠw‰ï�@“ú–{ƒAƒ‹ƒRƒ“�@ƒ‰ƒ“ƒ`ƒ‡ƒ“ƒZƒ~ƒi�[
—ߘa6”N9ŒŽ19-22“ú�@�@ƒAƒNƒŠƒG‚Ђ߂¶


ˆî’J�@‘å
‚܂Ƃ߂ĉð�à�I—Γà�áŽè�p�Å�Vƒ‰ƒCƒ“ƒiƒbƒv
‘æ35‰ñ“ú–{—Γà�áŠw‰ï�@ƒ��[ƒgƒjƒbƒeƒ“�@ƒ‚�[ƒjƒ“ƒOƒZƒ~ƒi�[
—ߘa6”N9ŒŽ19-22“ú�@�@ƒAƒNƒŠƒG‚Ђ߂¶


Inatani M
Let me talk about the criteria for usage requirements for iStent inject W in Japan
Glaucos Lancheon seminar
The 17th Joint Meeting of Japan-Korea-China Ophthalmologists, Congress Haneda Square, Nov 9


ˆî’J�@‘å
�V‚µ‚¢ƒvƒŒ�[ƒg•t‚«—Γà�áƒCƒ“ƒvƒ‰ƒ“ƒg�iƒA�[ƒ�ƒhƒNƒŠƒAƒpƒX�j‚Ì Žg—pŒoŒ±
‘½—l‰»‚·‚é—Γà�áŽè�p‚̃Aƒvƒ��[ƒ`�F4ƒ^ƒCƒv‚̃fƒoƒCƒX‘I‘ð‚ÆŽg‚¢‚±‚È‚µ�`�V‚µ‚¢MIGS‚Ì’ñˆÄ~�VŒ^ƒCƒ“ƒvƒ‰ƒ“ƒg‚Ü‚Å�`
‘æ78‰ñ“ú–{—Õ�°Šá‰ÈŠw‰ï�@JFCƒZ�[ƒ‹ƒXƒvƒ‰ƒ“ƒ‰ƒ“ƒ`ƒ‡ƒ“ƒZƒ~ƒi�[
—ߘa6”N11ŒŽ14-17“ú�@�@�‘—§‹ž“s�‘�Û‰ïŠÙ�EƒU�EƒvƒŠƒ“ƒX‹ž“s•óƒ–’r


ˆî’J�@‘å
Žg—p—vŒ�“™Šî�€‚ÌŽå‚ȉü’ù“_‚ð‰ð�à‚µ‚Ü‚·�I
‘�Šú—Γà�á‚ւ̃Aƒvƒ��[ƒ`�`”’“à�áŽè�p•¹—pŠá“àƒhƒŒ�[ƒ“�`Vol.4
‘æ78‰ñ“ú–{—Õ�°Šá‰ÈŠw‰ï�@ƒOƒ‰ƒEƒRƒXƒWƒƒƒpƒ“�@ƒ‰ƒ“ƒ`ƒ‡ƒ“ƒZƒ~ƒi�[
—ߘa6”N11ŒŽ14-17“ú�@�@�‘—§‹ž“s�‘�Û‰ïŠÙ�EƒU�EƒvƒŠƒ“ƒX‹ž“s•óƒ–’r


îà‘º�@‰À�O
�V‚µ‚¢“œ”A•a‰©”Á•‚Žî‚ÌŽ¡—ÃIƒvƒVƒ‡ƒ“
‘æ63‰ñ“ú–{–Ô–Œ�ÉŽq‘ÌŠw‰ï‘�‰ï�@ƒmƒoƒ‹ƒeƒBƒXƒtƒ@�[ƒ}Дޮ‰ïŽÐƒ‚�[ƒjƒ“ƒOƒZƒ~ƒi�[
—ߘa6”N12ŒŽ7“ú�@‘å�ã�‘�Û‰ï‹c�ê


îà‘º�@‰À�O
“à‰È‚ÆŠá‰È‚̘AŒg‚ªŽ¸–¾‚©‚瓜”A•aгŽÒ‚ð‹~‚¤
‘æ31‰ñ“ú–{“œ”A•aŠáŠw‰ï‘�‰ï�@‚í‚©‚à‚Æ�»–òƒ‚�[ƒjƒ“ƒOƒZƒ~ƒi�[
—ߘa7”N1ŒŽ25-26“ú�@�@‰«“êŽs


�y�‘“àŠw‰ï�i‘S�‘�j‰‰‘è”­•\�z


ŽR“c—Y‹M�AŽs‹´—SŽu�A�‚‘º‰À�O�A•½–ì—²—Y�AŽu‘º‰ë•F�A•Ä“cŒ\—C�A�¡–ìŒbˆê˜Y�Aˆî’J‘å
“œ”A•a�«‰©”Á•‚Žî‚ɑ΂·‚éƒuƒ�ƒ‹ƒVƒYƒ}ƒu�ÉŽq‘Ì“à’�ŽËŒã‚Ì‘O–[“àƒtƒŒƒA‚̕ω»
‘æ128‰ñ“ú–{Šá‰ÈŠw‰ï‘�‰ï�@
—ߘa6”N4ŒŽ18-21“ú�@�@“Œ‹ž�‘�ÛƒtƒH�[ƒ‰ƒ€


�™Œ´—F‰À�Aîà‘º‰À�O�AŽR“c—Y‹M�A�·‰ª�³˜a�AŒã‘ò�½�A‰Á“¡‹v”üŽq�A•½–ì‰À’j�A‘º”öŽjŽq�A�´�…”ü•ä�A“팴�呾˜Y�A‰ª–{–FŽj�A’|’†—DŠó�A‰ª•”’¼Žq�A�d�é’B�Æ�AŽ›�芰�l�A‰i—¢‘å—S�A“Ÿ�k‰F�A‹g“c–Î�¶�A�¬–¸�r‘¾˜Y�AˆÀ“c ‰À“ÞŽq�A�΋½‰ª �AàV“c�C�A“Œ“‡Žj–¾�Aˆî’J‘å
Ž‹Šo�áŠQŽÒŽè’ ‚ðŽæ“¾‚µ‚½“œ”A•aгŽÒ‚É‚¨‚¯‚éŽÀ‘Ô’²�¸
‘æ25‰ñ“ú–{ƒ��[ƒrƒWƒ‡ƒ“Šw‰ï
—ߘa6”N5ŒŽ24-26“ú�@�@‚³‚¢‚½‚ÜŽs


ŽR“c—Y‹M�A�‚‘º ‰À�O�A�™Œ´ —F‰À�Aˆî’J ‘å�AJ-CREST group
“œ”A•aгŽÒ‚ªŽ‹Šo�g�á‚Æ‚È‚Á‚½”wŒi‚ÉŠÖ‚·‚é‘S�‘’²�¸
‘æ30‰ñ“ú–{“œ”A•aŠáŠw‰ï‘�‰ï�@
—ߘa6”N6ŒŽ14-15“ú�@�Ô�âƒCƒ“ƒ^�[ƒVƒeƒBƒRƒ“ƒ“ƒtƒ@ƒŒƒ“ƒX


’Ò�@—²�G
CD157 ƒmƒbƒNƒAƒEƒgƒ}ƒEƒX‚Ö‚ÌL-ƒJƒ‹ƒmƒVƒ“‚ÌŒoŒû“Š—^‚Í‹}�«ƒXƒgƒŒƒX‚É‚æ‚è�ã�¸‚·‚éƒRƒ‹ƒ`ƒRƒXƒeƒ�ƒ“‚ðŒ¸Žã‚µ�A•ª—l�s“®‚ð—}�§‚·‚é
NEURO2024
—ߘa6”N7ŒŽ24-27“ú�@•Ÿ‰ªƒRƒ“ƒxƒ“ƒVƒ‡ƒ“ƒZƒ“ƒ^�[


Šâ핌’‘¾˜Y�Aˆî’J‘å
Surgical outcomes of Baerveldt versus Ahmed in neovascular glaucoma: A multicenter study
‘æ35‰ñ“ú–{—Γà�áŠw‰ï�@
—ߘa6”N9ŒŽ19-22“ú�@�@ƒAƒNƒŠƒG‚Ђ߂¶


—L‘º�®Œå�Aˆî’J‘å
�[‘wŠw�Kƒ‚ƒfƒ‹‚É‚æ‚é—Γà�á“_ŠáŽ¡—Â̗L–³‚Ì”»–¾
‘æ78‰ñ“ú–{—Õ�°Šá‰ÈŠw‰ï
—ߘa6”N11ŒŽ14-17“ú�@�‘—§‹ž“s�‘�Û‰ïŠÙ�EƒU�EƒvƒŠƒ“ƒX‹ž“s•óƒ–’r


’Ò—²�G�A‰|–{�’ˆê�Aˆî’J‘å
‚¤‚ÁŒŒ“û“ª‚𔺂¤Ž‹�_Œo�Ò�‘‰Š‚Ì1—á
‘æ62‰ñ“ú–{�_ŒoŠá‰ÈŠw‰ï‘�‰ï
—ߘa6”N11ŒŽ29-30“ú�@‹à‘òŽs


’O‰H�@�O�‚
”]“®–¬áŽ”j—ô‚É‚æ‚é‚­‚à–Œ‰º�oŒŒŒã‚É—¼ŠáŒõŠo‘rޏ‚ƂȂÁ‚½1—á
‘æ62‰ñ“ú–{�_ŒoŠá‰ÈŠw‰ï‘�‰ï
—ߘa6”N11ŒŽ29-30“ú�@‹à‘òŽs


�·‰ª�³˜a�AŽR“c—Y‹M�A�‚‘º‰À�O�Aˆî’J‘å�AJ-CREST group
“œ”A•a‰©”Á•‚Žî‚ɑ΂·‚é�ÉŽq‘ÌŽè�p‚Ì—LŒø�«‚ÉŠÖ‚·‚鑽Ž{�Ý•]‰¿
‘æ31‰ñ“ú–{“œ”A•aŠáŠw‰ï‘�‰ï
—ߘa7”N1ŒŽ25-26“ú�@�@‰«“êŽs


îà‘º‰À�O�AŽR“c—Y‹M�A�·‰ª�³˜a�Aˆî’J‘å
“œ”A•a‰©”Á•‚Žî‚ɑ΂·‚éƒtƒ@ƒŠƒVƒ}ƒu“Š—^Œã‚ÌŽc‘¶•‚Žî‚É‚¨‚¯‚é–Ñ�׌ŒŠÇᎂ̉ð�Í
‘æ31‰ñ“ú–{“œ”A•aŠáŠw‰ï‘�‰ï
—ߘa7”N1ŒŽ25-26“ú�@�@‰«“êŽs


�¼ˆä�ç—m�A�™Œ´—F‰À�Aîà‘º‰À�O�A“c’†”g�AŽR“c—Y‹M�A–Ú�•“”���A”ª“c‘ñ–ç�A•y“c—œ�¶�A“ì’J—R”üŽq�Aˆî’J‘å
“œ”A•aгŽÒ‚ɑ΂·‚éƒ��[ƒrƒWƒ‡ƒ“ƒPƒA‚Ì�Å“K‰»‚Ö‚ÌŽŽ‚Ý
‘æ31‰ñ“ú–{“œ”A•aŠáŠw‰ï‘�‰ï
—ߘa7”N1ŒŽ25-26“ú�@�@‰«“êŽs


�y�‘“àŠw‰ï�i‘S�‘�jƒ|ƒXƒ^�[”­•\�z


Œã‘ò�½�A�܈ä—C‰î�A�‚‘º‰À�O�Aˆî’J‘å
A case of globe rupture crossing calcified senile scleral plaque
‘æ78‰ñ“ú–{—Õ�°Šá‰ÈŠw‰ï
—ߘa6”N11ŒŽ14-17“ú�@�@�‘—§‹ž“s�‘�Û‰ïŠÙ�EƒU�EƒvƒŠƒ“ƒX‹ž“s•óƒ–’r


Šâ핌’‘¾˜Y�Aˆî’J‘å
IOP lowering effect of IOL refixation in eyes with high IOP by IOL subluxation
‘æ78‰ñ“ú–{—Õ�°Šá‰ÈŠw‰ï
—ߘa6”N11ŒŽ14-17“ú�@�@�‘—§‹ž“s�‘�Û‰ïŠÙ�EƒU�EƒvƒŠƒ“ƒX‹ž“s•óƒ–’r


—L‘º�®Œå�AŠâ핌’‘¾˜Y�A—é–Ø–œ—�Œb�Aˆî’J‘å
Grad-CAM‚ð—p‚¢‚½—Γà�á”»•Ê‹@ŠBŠw�Kƒ‚ƒfƒ‹‚É‚¨‚¯‚é”»’f�ª‹’‚̉Ž‹‰»
‘æ5‰ñ“ú–{Šá‰ÈAIŠw‰ï‘�‰ï
—ߘa6”N12ŒŽ1“ú�@‹ã�B‘åŠwˆãŠw•” •S”N�u“°


�™Œ´—F‰À�Aîà‘º‰À�O�AŒã‘ò�½�AŽR“c—Y‹M�A�·‰ª�³˜a�Aˆî’J‘å
•Ÿˆä‘åŠw‚ƉH“ñ�d‚Ë‚Á‚Ƃɂæ‚é•“I‚ȃ��[ƒrƒWƒ‡ƒ“Žx‰‡
‘æ31‰ñ“ú–{“œ”A•aŠáŠw‰ï‘�‰ï
—ߘa7”N1ŒŽ25-26“ú�@�@‰«“êŽs


�y�‘“àŠw‰ï�i’n•ûƒŒƒxƒ‹�j�µ‘Ò�u‰‰�z


ˆî’J�@‘å
[‚ä‚Á‚­‚è‰ð�à]—Γà�áŽè�pŽ¡—Ã2024‹à‘òŠá‰È�W’k‰ïƒXƒyƒVƒƒƒ‹�I
‘æ352‰ñ‹à‘òŠá‰È�W’k‰ï�h�™ŽR˜a‹v‹³Žö‚²‘Þ”C‹L”O�h�@
—ߘa6”N4ŒŽ7“ú�@�Î�쌧‹à‘òŽs


ˆî’J�@‘å
�Å‘¬‚ł킩‚é—Γà�á2024
–L’†ŽsˆãŽt‰ïŠá‰Èˆã‰ïŠw�pŒ¤‹†‰ï
—ߘa6”N5ŒŽ11“ú�@‘å�ã•{–L’†Žs


�‚‘º�@‰À�O
“�«DME‚ɑ΂µ‚ăoƒr�[ƒXƒ‚‚Ì“Á�«‚ð�¶‚©‚·Ž¡—Ã�í—ª
’†ŠOeƒZƒ~ƒi�[on Ophthalmology
—ߘa6”N5ŒŽ16“ú�@WEB”z�M


ŽR“c�@—Y‹M
–Ñ�׌ŒŠÇᎂ©‚猩‚é�RVEGF–òŽ¡—Ã’ï�R�«‚Ì“œ”A•a‰©”Á•‚Žî
GIFU Training of Ophthalmology
—ߘa6”N5ŒŽ23“ú�@WEB”z�M


�‚‘º�@‰À�O
“�«DME‚ɑ΂·‚é–Ñ�׌ŒŠÇᎂðˆÓޝ‚µ‚½ƒoƒr�[ƒXƒ‚‚É‚æ‚鎡—Ã�í—ª
Faricimab Expert Seminar in Himeji
—ߘa6”N5ŒŽ31“ú�@•ºŒÉŒ§•P˜HŽs


�‚‘º�@‰À�O
ƒxƒIƒrƒ…‚ª—LŒø‚ÈDME�Ç—á‚É“Á’¥‚Í‚ ‚é‚©�H
DME EXPERT MEETING IN TOKYO
—ߘa6”N6ŒŽ1“ú�@�@ƒOƒ‰ƒ“ƒhƒjƒbƒR�[“Œ‹ž‘ä�ê


�‚‘º�@‰À�O
ƒGƒrƒfƒ“ƒX‚ÉŠî‚­“�«DMEŽ¡—Ã�í—ª‚Ì�\’z‚ð–ÚŽw‚µ‚Ä
‘æ17‰ñState-of-the-Art webŠá‰ÈŒ¤‹†‰ï
—ߘa6”N6ŒŽ3“ú�@WEB”z�M


�‚‘º�@‰À�O
ƒGƒrƒfƒ“ƒX‚ÉŠî‚­“�«DME‚ÌŽ¡—Ã�í—ª�\’z‚ð–ÚŽw‚µ‚Ä
DME�fŽ@ƒGƒLƒXƒp�[ƒgƒtƒH�[ƒ‰ƒ€
—ߘa6”N6ŒŽ9“ú�@–kŠC“¹ŽD–yŽs


�‚‘º�@‰À�O
DMEŽ¡—Âɂ¨‚¢‚ăxƒIƒrƒ…‚ª—LŒø‚È�Ç—á‚É“Á’¥‚Í‚ ‚é‚©�H
Novartis DME Web Seminar
—ߘa6”N6ŒŽ19“ú�@WEB”z�M


ˆî’J�@‘å
[‚ä‚Á‚­‚è‰ð�à]—Γà�á“_Šá–ò2024
‘æ15‰ñ“Œ–M‘åŠw�²‘q•a‰@Šá‰ÈƒtƒH�[ƒ‰ƒ€
—ߘa6”N6ŒŽ22“ú�@�ç—tŽs


�‚‘º�@‰À�O
“�«DME‚Ì�Ž•ž‚ð–ÚŽw‚¹‚éƒoƒr�[ƒXƒ‚‚Ì“Á�«
CHUGAI Ophthalmology Symposium 2024 in Osaka
—ߘa6”N6ŒŽ22“ú�@‘å�ãŽs


�‚‘º�@‰À�O
“�«DME‚ɑ΂µ‚ăoƒr�[ƒXƒ‚‚Ì“Á�«‚ð�¶‚©‚·Ž¡—Ã�í—ª
‘æ4‰ñ�L“‡–Ô–Œ‰©”Á޾гƒZƒ~ƒi�[
—ߘa6”N6ŒŽ27“ú�@Web”z�M


�‚‘º�@‰À�O
“�«DME‚ɑ΂µ‚ătƒ@ƒŠƒVƒ}ƒu‚Ì“Á�«‚ð�¶‚©‚¹‚é‚©�H
“Þ—ÇŒ§Šá‰È–œ—tƒtƒH�[ƒ‰ƒ€
—ߘa6”N6ŒŽ29“ú�@“Þ—ÇŒ§Š€Œ´Žs


ˆî’J�@‘å
�y‚ä‚Á‚­‚è‰ð�à�z—Γà�á“_Šá–ò2024
Pearls of Glaucoma 2024
—ߘa6”N7ŒŽ13“ú�@–¼ŒÃ‰®Žs


ˆî’J�@‘å
[‚ä‚Á‚­‚è‰ð�à]—Γà�á“_Šá–ò2024
’¹ŽæŒ§Šá‰ÈƒtƒH�[ƒ‰ƒ€
—ߘa6”N7ŒŽ20“ú�@�@’¹ŽæŒ§•ÄŽqŽs


ˆî’J�@‘å
�Å‘¬‚ł킩‚é—Γà�Ꭱ—Ã2024
Otsuka Ophthalmology Seminar in •Ÿˆä
—ߘa6”N7ŒŽ26“ú�@�@•Ÿˆä�¤�H‰ï‹c�Š


�‚‘º�@‰À�O
ƒxƒIƒrƒ…‚ª’˜Œø‚·‚éDME�Ç—á‚Ì“Á’¥‚ð�l‚¦‚悤
���ì‘åŠw-ˆ¤•Q‘åŠw�‡“¯ƒJƒ“ƒtƒ@ƒŒƒ“ƒX
—ߘa6”N7ŒŽ27“ú�@�@�‚�¼Žs


ˆî’J�@‘å
�y‚ä‚Á‚­‚è‰ð�à�z—Γà�áŽè�pƒAƒbƒvƒf�[ƒg2024
‘æ45‰ñ“ŒŠC—Γà�á‚̉ï
—ߘa6”N7ŒŽ28“ú�@–¼ŒÃ‰®Žs


�‚‘º�@‰À�O
“�«DME‚ɑ΂·‚é�RVEGF–ò‚Ì“K�«‚ð�l‚¦‚悤
‘æ144‰ñŽRŒ`Šá‰ÈŒ¤‹†‰ï
—ߘa6”N8ŒŽ4“ú�@�@ŽRŒ`Œ§ŽRŒ`Žs


�‚‘º�@‰À�O
DME‚Ö‚Ì‘�ŠúŽ¡—Éî“ü‚É‚¨‚¯‚éƒxƒIƒrƒ…‚Ö‚ÌŠú‘Ò
Novartis DME Web Seminar
—ߘa6”N8ŒŽ21“ú�@Web”z�M


—L‘º�@�®Œå
‘åŠw•a‰@‚É‚¨‚¯‚é—Γà�á�fŽ@
AP-7700 WebƒJƒ“ƒtƒ@ƒŒƒ“ƒX�L‚ª‚鎩“®Ž‹–ìŒv‚Ì‘I‘ðŽˆ
—ߘa6”N8ŒŽ23“ú�@�@Web”z�M


ˆî’J�@‘å
—Γà�á“_Šá–ò2024�`Ž¡—Ë­‰»‚ɂ͔z�‡�Ü‚©�H�`
State-of-the-art Šá‰È�f—ÃZƒ~ƒi�[
—ߘa6”N9ŒŽ3“ú�@�@WEB”z�M


�‚‘º�@‰À�O
“�«DME‚ɑ΂µ‚ăoƒr�[ƒXƒ‚‚Ì“Á�«‚ð�¶‚©‚·Ž¡—Ã�í—ª
�VŠƒŒ§ƒoƒr�[ƒXƒ‚”­”„2Žü”N‹L”O�u‰‰‰ï
—ߘa6”N9ŒŽ7“ú�@�VŠƒŽs


�‚‘º�@‰À�O
“�«DME‚ɑ΂µ‚ătƒ@ƒŠƒVƒ}ƒu‚Ì“Á�«‚ð�¶‚©‚¹‚é‚©�H
‘æ65‰ñ‚Æ‚â‚ÜŠá‰ÈŠw�p�u‰‰‰ï
—ߘa6”N10ŒŽ5“ú�@•xŽRŽs


ˆî’J�@‘å
ƒvƒŠƒU�[ƒtƒ�‚Ö‚ÌŠú‘Ò
ƒvƒŠƒU�[ƒtƒ�®ƒ}ƒCƒNƒ�ƒVƒƒƒ“ƒg”­”„1Žü”N‹L”OWeb�u‰‰‰ï
—ߘa6”N10ŒŽ9“ú�@Web”z�M


�‚‘º�@‰À�O
DME‚ɑ΂·‚é�RVEGFŽ¡—Â̕W�€‰»‚Æ’nˆæ˜AŒg
8�†�üŠá‰È’nˆæ˜AŒg‚̉ï
—ߘa6”N10ŒŽ11“ú�@�Î�쌧


ˆî’J�@‘å
[‚ä‚Á‚­‚è‰ð�à]—Γà�á“_Šá–ò2024
‘æ198‰ñ‰ªŽRŒ§Šá‰Èˆã‰ï�¶ŠU‹³ˆç�u�À
—ߘa6”N11ŒŽ23“ú�@�@‰ªŽRŒ§‰ªŽRŽs


ˆî’J�@‘å
[‚ä‚Á‚­‚è‰ð�à]—Γà�á”z�‡“_Šá–ò 2025:ƒOƒ‰ƒAƒ‹ƒtƒ@‚ÌŽg‚¢‚Ç‚±‚ë‚̓RƒR�I
Glaucoma Update in Aomori
—ߘa7”N1ŒŽ18“ú�@�Â�XŒ§�O‘OŽs


ˆî’J�@‘å
�m‚ä‚Á‚­‚è‰ð�à�n—Γà�áŽè�pŽ¡—Ã2025
‘æ15‰ñ–k‹ã�B�R‰Á—îŠá޾гŒ¤‹†‰ï
—ߘa7”N1ŒŽ23“ú�@�@•Ÿ‰ªŒ§


ˆî’J�@‘å
—Γà�áŽè�pŽ¡—ÂÌ�i•à
Œcœä‹`�m‘åŠwˆãŠw•”Šá‰ÈŠw‹³Žº –Ø—jƒJƒ“ƒtƒ@ƒŒƒ“ƒX
—ߘa7”N2ŒŽ6“ú�@ “Œ‹ž“s


ˆî’J�@‘å
[‚ä‚Á‚­‚è‰ð�à]—Γà�á”z�‡“_Šá–ò 2025:ƒOƒ‰ƒAƒ‹ƒtƒ@‚ÌŽg‚¢‚Ç‚±‚ë‚̓RƒR�I
ƒOƒ‰ƒAƒ‹ƒtƒ@2Žü”N‹L”O�u‰‰‰ï ROCK Symposium 2025 in ’†Žl�‘
—ߘa7”N2ŒŽ22“ú�@‰ªŽRŒ§‰ªŽRŽs


îà‘º�@‰À�O
“œ”A•a‚É‚æ‚鎸–¾‚ð–h‚®‚½‚߂ɉ½‚ª‚Å‚«‚é‚©�H
‘æ54‰ñŠá‰Èˆã—ÃtƒH�[ƒ‰ƒ€
—ߘa7”N3ŒŽ9“ú�@“¿“‡Žs


ˆî’J�@‘å
[‚ä‚Á‚­‚è‰ð�à]—Γà�á”z�‡“_Šá–ò 2025 ƒOƒ‰ƒAƒ‹ƒtƒ@‚ÌŽg‚¢‚Ç‚±‚ë‚̓RƒR�I
Kowa WEBƒJƒ“ƒtƒ@ƒŒƒ“ƒX
—ߘa7”N3ŒŽ13“ú�@Web”z�M


ˆî’J�@‘å
[‚ä‚Á‚­‚è‰ð�à]—Γà�áŽè�pŽ¡—Ã2025
‘æ25‰ñ–kŠC“¹Šá‰ÈƒtƒH�[ƒ‰ƒ€
—ߘa7”N3ŒŽ15“ú�@–kŠC“¹ŽD–yŽs


�y�‘“àŠw‰ï�i’n•ûƒŒƒxƒ‹�j‰‰‘è”­•\�z


Žs‹´�@—SŽu
“œ”A•a�«‰©”Á•‚Žî‚ɑ΂·‚éƒuƒ�ƒ‹ƒVƒYƒ}ƒuŽg—p‘OŒã‚Ì‘O–[“àƒtƒŒƒA‚̕ω»
‘æ8‰ñ–k—¤4‘åŠwŠá‰È�‡“¯Œ¤‹†‰ï
—ߘa6”N5ŒŽ17“ú�@�@•ŸˆäƒtƒFƒjƒbƒNƒXƒzƒeƒ‹


áÁ“c˜Ð‹G�A�™Œ´—F‰À�Aîà‘º‰À�O�AŽR“c—Y‹M�AJ-CREST group�Aˆî’J‘å
“œ”A•a‚ÅŽ‹Šo�g�á‚Æ”F’肳‚ê‚½Š³ŽÒ‚Ì‘S�‘ŽÀ‘Ô’²�¸
‘æ89‰ñ•xŽRŠá‰È�W’k‰ï
—ߘa6”N6ŒŽ16“ú�@�@•xŽRŽs


�´�…�ç—Ç�A�™Œ´—F‰À�Aîà‘º‰À�O�AŽR“c—Y‹M�AJ-CREST group�Aˆî’J‘å
“œ”A•a‚ÅŽ‹Šo�g�á‚Æ”F’肳‚ê‚½Š³ŽÒ‚Ì‘S�‘ŽÀ‘Ô’²�¸
‘æ79‰ñ•ŸˆäŒ§Šá‰È�W’k‰ï
—ߘa6”N9ŒŽ7“ú�@•Ÿˆä�¤�H‰ï‹c�Š


Šâí•�@Œ’‘¾˜Y
ŒŒŠÇ�V�¶—Γà�á‚ɑ΂·‚éƒoƒ‹ƒxƒ‹ƒg‚Ì—LŒø�«
‘æ14‰ñ—Γà�áƒ`ƒ…�[ƒuŽè�p‚̉ï
—ߘa6”N11ŒŽ16“ú�@ƒzƒeƒ‹ƒI�[ƒNƒ‰‹ž“s


—F“c�Ê�…�A�™Œ´—F‰À�Aîà‘º‰À�O�AŽR“c—Y‹M�AJ-CREST group�Aˆî’J‘å
“œ”A•a‚ÅŽ‹Šo�g�á‚Æ”F’肳‚ê‚½Š³ŽÒ‚Ì‘S�‘ŽÀ‘Ô’²�¸
‘æ44‰ñ‹à‘òˆã‰È‘åŠwŠá‰ÈŒ¤‹†‰ï
—ߘa6”N11ŒŽ16“ú�@�@‹à‘òŽs


áÁ“c˜Ð‹G�AŠâ핌’‘¾˜Y�A�¬�X—Á•½�A—L‘º�®Œå�A�‚‘º‰À�O�Aˆî’J‘å
Šá“àƒŒƒ“ƒYˆŸ’E‰P—Γà�á‚ɑ΂·‚éŠá“àƒŒƒ“ƒY�ČŒè�p‚̊ሳ‰º�~Œø‰Ê
‘æ90‰ñ•xŽRŠá‰È�W’k‰ï
—ߘa6”N11ŒŽ23“ú�@•xŽRŽs


áÁ“c˜Ð‹G�AŠâ핌’‘¾˜Y�A�¬�X—Á•½�A—L‘º�®Œå�A�‚‘º‰À�O�Aˆî’J‘å
Šá“àƒŒƒ“ƒYˆŸ’E‰P—Γà�á‚ɑ΂·‚éŠá“àƒŒƒ“ƒY�ČŒè�p‚̊ሳ‰º�~Œø‰Ê
‘æ353‰ñ‹à‘òŠá‰È�W’k‰ï
—ߘa6”N12ŒŽ15“ú�@‹à‘òŽs


áÁ“c˜Ð‹G
’·ŠúŽû�Ú•i‚ɑ΂·‚é‘I’è—×{‚Ç‚¤‚µ‚Ä‚é�H
‘æ80‰ñ•ŸˆäŒ§Šá‰È�W’k‰ï
—ߘa7”N1ŒŽ11“ú�@•Ÿˆä�¤�H‰ï‹c�Š


Œã‘ò�@�½
’¿‚µ‚¢Šá‹…”j—ô‚̈ê—á
‘æ5‰ñ–Ô–ŒHOPE‚̉ï
—ߘa7”N3ŒŽ7“ú�@Web”z�M